With such insights, this manuscript presents a comprehensive discussion on the sequential biochemical events in estrogen-activated cell signaling pathways in NSCLC complications with a focus on the ER/GPER/EGFR/ERR regulatory mechanism alongside the NSCLC treating anti-estrogen targeted therapies. Here, GPER1 is linked to non-small cell lung carcinoma.